On Monday, the World Health Organization (WHO) stated that it was anticipating an additional piece of information from Bharat Biotech on its Covaxin that is currently under examination by the organization’s experts in order to attain a grant of Emergency Use Listing (EUL), stated reports. The WHO also highlighted that the additional piece of information was expected on Monday.
We are aware that many people are waiting for WHO’s recommendation for Covaxin to be included in the #COVID19 Emergency Use Listing, but we cannot cut corners - before recommending a product for emergency use, we must evaluate it thoroughly to make sure it is safe and effective. pic.twitter.com/GDx8GAc1KU
— World Health Organization (WHO) (@WHO) October 18, 2021
The WHO took to Twitter, adding that it couldn’t “cut corners” and that the time period for its Emergency Use Listing was reliant on how promptly the manufacturers could offer the necessary information. The WHO is said to have elaborated that whilst they are aware that many are awaiting the their recommendation for Covaxin to be put in the Emergency Use Listing, they couldn’t cut corners prior to recommending it for emergency use since it needs to be evaluated comprehensively to ensure that it is safe as well as effective.
They also mentioned that the manufacturer has been providing information to the authority on a rolling basis which is being examined by the WHO experts. The organization is anticipating one more piece of data. In addition to this, they also stated that the duration for the Emergency Use Listing process is subject to how promptly, manufacturers can offer the information needed for the organization to study its quality, efficacy, safety, aptness for low- and middle-income countries.
The WHO cited that upon the attainment of information that answers all questions, the organization along with its Technical Advisory Group will finish the assessment and reach a decision. Furthermore, Chief Scientist, World Health Organization Dr Soumya Swaminathan took to Twitter to state that the technical advisory group will meet on 26 October to discuss the EUL for Covaxin.
The technical advisory group will meet on Oct 26th to consider EUL for #Covaxin. @WHO has been working closely with @BharatBiotech to complete the dossier. Our goal is to have a broad portfolio of vaccines approved for emergency use & to expand access to populations everywhere https://t.co/lqQIyqItF9
— Soumya Swaminathan (@doctorsoumya) October 17, 2021
Share
Tweet
